MX2007010664A - Nuevas composiciones farmaceuticas que comprenden al menos un inhibidor directo de la trombina para el tratamiento de la trombosis. - Google Patents

Nuevas composiciones farmaceuticas que comprenden al menos un inhibidor directo de la trombina para el tratamiento de la trombosis.

Info

Publication number
MX2007010664A
MX2007010664A MX2007010664A MX2007010664A MX2007010664A MX 2007010664 A MX2007010664 A MX 2007010664A MX 2007010664 A MX2007010664 A MX 2007010664A MX 2007010664 A MX2007010664 A MX 2007010664A MX 2007010664 A MX2007010664 A MX 2007010664A
Authority
MX
Mexico
Prior art keywords
sub
thrombosis
treatment
inhibitors
antagonists
Prior art date
Application number
MX2007010664A
Other languages
English (en)
Spanish (es)
Inventor
James C Gilbert
Paul A Reilly
Thomas H Mueller
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36423564&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2007010664(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of MX2007010664A publication Critical patent/MX2007010664A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A61K38/58—Protease inhibitors from animals; from humans from leeches, e.g. hirudin, eglin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2007010664A 2005-03-29 2006-03-27 Nuevas composiciones farmaceuticas que comprenden al menos un inhibidor directo de la trombina para el tratamiento de la trombosis. MX2007010664A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05006711 2005-03-29
PCT/EP2006/061046 WO2006103206A2 (en) 2005-03-29 2006-03-27 Combinations comprising at least one direct thrombin inhibitor for the treatment of thrombosis

Publications (1)

Publication Number Publication Date
MX2007010664A true MX2007010664A (es) 2007-12-12

Family

ID=36423564

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007010664A MX2007010664A (es) 2005-03-29 2006-03-27 Nuevas composiciones farmaceuticas que comprenden al menos un inhibidor directo de la trombina para el tratamiento de la trombosis.

Country Status (19)

Country Link
US (2) US20060222640A1 (OSRAM)
EP (1) EP1885354A2 (OSRAM)
JP (1) JP2008534552A (OSRAM)
KR (1) KR20070116936A (OSRAM)
CN (1) CN101151030A (OSRAM)
AR (1) AR056291A1 (OSRAM)
AU (1) AU2006228600A1 (OSRAM)
BR (1) BRPI0608656A2 (OSRAM)
CA (1) CA2602563A1 (OSRAM)
CL (1) CL2010000395A1 (OSRAM)
EA (1) EA015122B1 (OSRAM)
IL (1) IL186267A0 (OSRAM)
MX (1) MX2007010664A (OSRAM)
NO (1) NO20074149L (OSRAM)
NZ (1) NZ562775A (OSRAM)
TW (1) TW200722089A (OSRAM)
UA (1) UA92603C2 (OSRAM)
WO (1) WO2006103206A2 (OSRAM)
ZA (1) ZA200706698B (OSRAM)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8906894B1 (en) 2000-07-27 2014-12-09 Thomas N. Thomas Methods for preventing and treating thrombotic disorders
US20030181488A1 (en) 2002-03-07 2003-09-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof
DE10339862A1 (de) * 2003-08-29 2005-03-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)- phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester-Methansulfonat und dessen Verwendung als Arzneimittel
IL159273A0 (en) * 2003-12-09 2004-06-01 Transpharma Medical Ltd Transdermal delivery system for sustained release of polypeptides
CA2610757A1 (en) * 2005-06-10 2006-12-14 Transpharma Medical, Ltd. Patch for transdermal drug delivery
EP2043632A2 (en) * 2006-07-17 2009-04-08 Boehringer Ingelheim International GmbH New indications for direct thrombin inhibitors
US20100087488A1 (en) * 2006-10-10 2010-04-08 Boehringer Ingelheim International Gmgh Physiologically Acceptable Salts of 3-[(2--1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester
DE102006051625A1 (de) 2006-11-02 2008-05-08 Bayer Materialscience Ag Kombinationstherapie substituierter Oxazolidinone
WO2009057112A2 (en) * 2007-10-29 2009-05-07 Transpharma Medical, Ltd. Vertical patch drying
WO2010013231A2 (en) * 2008-07-29 2010-02-04 Yeda Research And Development Co. Ltd. Modulation of coagulation factors and effectors of same for control of transplant organ size
EP2323605A4 (en) * 2008-09-10 2014-02-05 Syneron Medical Ltd TRANSDERMAL RELEASE OF OLIGOSACCHARIDES
TW201031651A (en) * 2008-11-11 2010-09-01 Boehringer Ingelheim Int Method for treating or preventing thrombosis using dabigatran etexilate or a salt thereof with improved efficacy over conventional warfarin therapy
AR074313A1 (es) 2008-11-11 2011-01-05 Boehringer Ingelheim Int Metodo para tratar o prevenir la trombosis utilizando etexilato de dabigatran o una sal del mismo. uso. kit
CA2738885A1 (en) * 2008-11-11 2010-05-20 Boehringer Ingelheim International Gmbh Method for treating or preventing thrombosis using dabigatran etexilate or a salt thereof with improved efficacy over conventional warfarin therapy
EP2384196B1 (en) * 2008-12-30 2017-09-13 Johansson, Pär Methods of identifying critically ill patients at increased risk of development of organ failure and compounds for the treatment hereof
PL2667878T3 (pl) * 2011-01-25 2016-10-31 Kompozycje i sposoby transplantacji komórek
CN102250099B (zh) * 2011-05-16 2013-10-16 中国药科大学 一类非肽类抗凝血酶抑制剂、其制法以及医药用途
EP2806879B1 (en) 2012-01-25 2019-03-06 Université Catholique de Louvain Compositions and methods for cell transplantation
WO2014001220A1 (en) 2012-06-25 2014-01-03 Boehringer Ingelheim International Gmbh Method for prevention of stroke
EP2722034B1 (en) * 2012-10-19 2020-09-16 Sanovel Ilac Sanayi ve Ticaret A.S. Oral pharmaceutical formulations comprising dabigatran
EP2722033A1 (en) * 2012-10-19 2014-04-23 Sanovel Ilac Sanayi ve Ticaret A.S. Pharmaceutical Compositions of Dabigatran Free Base
JP6474394B2 (ja) 2013-07-05 2019-02-27 ユニベルシテ カトリック ドゥ ルーベン ヒト成体肝臓幹細胞由来の馴化培地および肝臓障害の治療におけるその使用
DE102014108210A1 (de) 2014-06-11 2015-12-17 Dietrich Gulba Rodentizid
CN105250286A (zh) * 2015-11-13 2016-01-20 谭惠娟 一种抗血栓组合物
CN108236612A (zh) * 2016-12-27 2018-07-03 李志忠 用于冠脉介入手术中抗凝的组合产品及其用途
WO2020180489A1 (en) * 2019-03-06 2020-09-10 University Of Rochester Anticoagulant compositions and uses thereof
US11654036B2 (en) 2020-05-26 2023-05-23 Elixir Medical Corporation Anticoagulant compounds and methods and devices for their use
CN115192691B (zh) * 2022-08-31 2025-03-04 晓恩医药包装材料(安庆)有限公司 一种阿加曲班注射液及预灌封注射器

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6087380A (en) * 1949-11-24 2000-07-11 Boehringer Ingelheim Pharma Kg Disubstituted bicyclic heterocycles, the preparations and the use thereof as pharmaceutical compositions
US5510330A (en) * 1994-03-25 1996-04-23 Boehringer Mannheim Gmbh Combinations of thrombolytically active proteins and non-heparin anticoagulants, and uses thereof.
NZ286082A (en) * 1995-03-15 1998-09-24 Behringwerke Ag Method of treating acute myocardial infarction with hirudin and acetylsalicylic acid in patients not undergoing thrombolytic treatment
FR2744918B1 (fr) * 1996-02-19 1998-05-07 Sanofi Sa Nouvelles associations de principes actifs contenant un derive de thieno(3,2-c)pyridine et un antithrombotique
PE121699A1 (es) * 1997-02-18 1999-12-08 Boehringer Ingelheim Pharma Heterociclos biciclicos disustituidos como inhibidores de la trombina
US6414008B1 (en) * 1997-04-29 2002-07-02 Boehringer Ingelheim Pharma Kg Disubstituted bicyclic heterocycles, the preparation thereof, and their use as pharmaceutical compositions
DE19834751A1 (de) * 1998-08-01 2000-02-03 Boehringer Ingelheim Pharma Disubstituierte bicyclische Heterocyclen, ihre Herstellung und ihre Verwendung als Arzneimittel
GB9930540D0 (en) * 1999-12-23 2000-02-16 Rhone Poulenc Rorer Pharma Chemical compounds
GB0014134D0 (en) * 2000-06-10 2000-08-02 Astrazeneca Ab Combination therapy
US8183206B2 (en) * 2001-09-14 2012-05-22 Mitsubishi Tanabe Pharma Corporation Drugs comprising combination of antithrombotic agent with pyrazolone derivative
DK1485094T4 (da) * 2002-03-07 2020-06-22 Boehringer Ingelheim Int Doseringsform til oral indgivelse af 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1h-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsyre-ethylester eller dets salte
DE10235639A1 (de) * 2002-08-02 2004-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Prodrugs von 1-Methyl-2-(4-amidinophenylaminomethyl)-benzimidazol-5-yl-carbonsäure-(N-2-pyridyl-N-2-hydroxycarbonylethyl)-amid, ihre Herstellung und ihre Verwendung als Arzneimittel
BRPI0409796A (pt) * 2003-04-24 2006-05-30 Boehringer Ingelheim Int uso de dipiridamol ou mopidamol para tratamento e prevenção de doenças tromboembolìticas e distúrbios provocados pela formação excessiva de trombina e/ou pela expressão elevada de receptores de trombina

Also Published As

Publication number Publication date
WO2006103206A3 (en) 2007-01-11
CN101151030A (zh) 2008-03-26
US20100184729A1 (en) 2010-07-22
NO20074149L (no) 2007-12-11
AR056291A1 (es) 2007-10-03
US20060222640A1 (en) 2006-10-05
BRPI0608656A2 (pt) 2010-01-19
CA2602563A1 (en) 2006-10-05
IL186267A0 (en) 2008-01-20
TW200722089A (en) 2007-06-16
JP2008534552A (ja) 2008-08-28
NZ562775A (en) 2011-03-31
AU2006228600A1 (en) 2006-10-05
WO2006103206A2 (en) 2006-10-05
EA200701841A1 (ru) 2008-02-28
EA015122B1 (ru) 2011-06-30
EP1885354A2 (en) 2008-02-13
KR20070116936A (ko) 2007-12-11
UA92603C2 (ru) 2010-11-25
CL2010000395A1 (es) 2010-08-20
ZA200706698B (en) 2008-12-31

Similar Documents

Publication Publication Date Title
MX2007010664A (es) Nuevas composiciones farmaceuticas que comprenden al menos un inhibidor directo de la trombina para el tratamiento de la trombosis.
IS8502A (is) Azatvíhringja heteróhringir sem kannabínóíð-viðtakastillar
SE0302760D0 (sv) New compounds
WO2006053342A3 (en) Integrin antagonists useful as anticancer agents
MXPA05012025A (es) Imidazo y tiazolopiridinas como inhibidores de cinasa jak3.
ATE362932T1 (de) Azaindolverbindungen als kinaseinhibitoren
DE602004008098D1 (de) Substituierte 2h-ä1,2,4ütriazoloä4,3-aüpyrazine als gsk-3-inhibitoren
MX2007004699A (es) Derivados de indol y bencimidazol.
BR0210507A (pt) Azaindóis
UA86591C2 (ru) Пирролодигидроизохинолины как ингибиторы pde10, фармацевтическая композиция на их основе
ATE413388T1 (de) Muskarin antagonisten
TW200612958A (en) Substituted imidazole derivatives
MX2009004746A (es) Derivados de 1,2,4-triazol como inhibidores del receptor sigma.
MY145074A (en) Thiazolidin-4-one derivatives
WO2009065922A3 (de) Organische verbindungen
MX2010003849A (es) Antagonistas de cgrp.
MXPA03010766A (es) Nuevos compuestos y composiciones como inhibicores de las catepsinas.
TW200745062A (en) Macrocyclic factor VIIA inhibitors useful as anticoagulants
MY147188A (en) Substituted imidazole compounds as ksp inhibitors
UA74430C2 (uk) Похідні фенілгетероциклічних етерів як інгібітори зворотного захоплення серотоніну
WO2005049604A3 (en) Antithrombotic aromatic ethers
WO2004069145A3 (en) Anticancer compounds, process for their preparation and pharmaceutical compositions containing them
WO2009065921A3 (de) Organischeverbindungen
ATE316972T1 (de) Trizyklische crf rezeptor antagonisten
UY27717A1 (es) Nuevos derivados de azepano.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal